How These Biotech Stocks are Faring? -- Corbus Pharma, Advaxis, Vanda Pharma, and Nivalis Therapeutics

Tuesday, March 7, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 7, 2017 /PRNewswire/ --

On Monday, March 06, 2017, the NASDAQ Composite,

the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Monday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, assessed
the following Biotech equities this morning: Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), Advaxis Inc. (NASDAQ: ADXS), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Nivalis Therapeutics Inc. (NASDAQ: NVLS). Download the free research reports on these stocks today:

Corbus Pharma

Norwood, Massachusetts-based Corbus Pharmaceuticals Holdings Inc.'s stock finished Monday's session 1.08% lower at $9.20 with a total volume of 1.10 million shares traded. Over the last one month and the previous three months, Corbus Pharmaceuticals Holdings' shares have surged 39.39% and 26.03%, respectively. Furthermore, the stock has rallied 457.58% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 17.37% and 58.22%, respectively. Shares of Corbus Pharma, which focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases, have a Relative Strength Index (RSI) of 61.60. See our free and comprehensive research report on CRBP at:


Princeton, New Jersey-based Advaxis Inc.'s stock advanced 4.12%, to close the day at $9.60. The stock recorded a trading volume of 1.81 million shares, which was above its three months average volume of 673,850 shares. Advaxis' shares have gained 6.90% in the last one month, 19.70% in the previous three months and 11.11% in the past one year. The Company's shares are trading 12.11% and 1.46% above its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the US, have an RSI of 62.73. ADXS free research report PDF is just a click away at:

Vanda Pharma

On Monday, shares in Washington, the District of Columbia headquartered Vanda Pharmaceuticals Inc. ended the session 1.40% higher at $14.45 with a total volume of 509,553 shares traded. Vanda Pharma's shares have gained 6.64% in the last one month and 82.45% in the previous one year. The stock is trading 3.26% above its 200-day moving average. Moreover, shares of the Company, which focuses on the development and commercialization of products for the treatment of central nervous system disorders, have an RSI of 50.49. Sign up for your complimentary report on VNDA at:

Nivalis Therapeutics

On Monday, shares in Boulder, Colorado headquartered Nivalis Therapeutics Inc. recorded a trading volume of 68,500 shares. The stock ended the day 1.67% lower at $2.65. Nivalis Therapeutics' stock has surged 16.23% in the last one month and 28.02% in the previous three months. The Company is trading above its 50-day moving average by 13.19%. Furthermore, shares of Nivalis Therapeutics, which focuses on the discovery and development of product candidates for patients with cystic fibrosis in the US, have an RSI of 57.08. Register for free on and download the latest research report on NVLS at:

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store